Zacks Research Has Bearish Forecast for IRWD Q3 Earnings

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) – Equities research analysts at Zacks Research decreased their Q3 2026 earnings estimates for Ironwood Pharmaceuticals in a research note issued on Wednesday, March 26th. Zacks Research analyst R. Department now forecasts that the biotechnology company will post earnings per share of $0.07 for the quarter, down from their previous estimate of $0.08. The consensus estimate for Ironwood Pharmaceuticals’ current full-year earnings is $0.10 per share. Zacks Research also issued estimates for Ironwood Pharmaceuticals’ Q4 2026 earnings at $0.06 EPS and FY2026 earnings at $0.23 EPS.

A number of other equities analysts have also weighed in on IRWD. JMP Securities decreased their price objective on shares of Ironwood Pharmaceuticals from $23.00 to $14.00 and set a “market outperform” rating for the company in a report on Thursday, January 30th. Craig Hallum lowered their price objective on Ironwood Pharmaceuticals from $10.00 to $8.00 and set a “buy” rating on the stock in a research report on Wednesday, January 22nd. Finally, StockNews.com lowered shares of Ironwood Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Friday, March 21st. Four research analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. According to data from MarketBeat.com, Ironwood Pharmaceuticals has a consensus rating of “Hold” and an average target price of $8.60.

Ironwood Pharmaceuticals Stock Performance

Shares of IRWD stock opened at $1.46 on Friday. The stock has a market cap of $233.64 million, a PE ratio of -48.67 and a beta of 0.37. Ironwood Pharmaceuticals has a 12 month low of $1.34 and a 12 month high of $9.01. The company’s fifty day moving average price is $2.09 and its 200-day moving average price is $3.41.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last released its quarterly earnings results on Thursday, February 27th. The biotechnology company reported $0.02 EPS for the quarter, missing analysts’ consensus estimates of $0.10 by ($0.08). The business had revenue of $90.55 million for the quarter, compared to the consensus estimate of $93.85 million. Ironwood Pharmaceuticals had a negative net margin of 0.65% and a negative return on equity of 0.96%.

Institutional Trading of Ironwood Pharmaceuticals

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Point72 Asia Singapore Pte. Ltd. purchased a new position in Ironwood Pharmaceuticals during the 4th quarter valued at about $36,000. Journey Strategic Wealth LLC acquired a new stake in Ironwood Pharmaceuticals in the fourth quarter valued at $45,000. Catalyst Funds Management Pty Ltd acquired a new stake in shares of Ironwood Pharmaceuticals during the 4th quarter worth about $47,000. Envestnet Asset Management Inc. purchased a new stake in shares of Ironwood Pharmaceuticals during the 4th quarter worth approximately $50,000. Finally, Xponance Inc. purchased a new stake in Ironwood Pharmaceuticals in the fourth quarter valued at $50,000.

Insiders Place Their Bets

In related news, CMO Michael Shetzline sold 41,269 shares of Ironwood Pharmaceuticals stock in a transaction on Monday, February 10th. The shares were sold at an average price of $1.76, for a total value of $72,633.44. Following the sale, the chief marketing officer now owns 554,007 shares of the company’s stock, valued at approximately $975,052.32. This trade represents a 6.93 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Thomas A. Mccourt sold 139,064 shares of the firm’s stock in a transaction dated Monday, February 10th. The shares were sold at an average price of $1.76, for a total transaction of $244,752.64. Following the completion of the transaction, the chief executive officer now directly owns 1,160,634 shares in the company, valued at $2,042,715.84. This represents a 10.70 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 192,381 shares of company stock valued at $338,591. Insiders own 12.90% of the company’s stock.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.